Hitting the bull's eye: Targeting HMGA1 in cancer stem cells

Expert Review of Anticancer Therapy

Volumn 14, Issue 1, 2014, Pages 23-30

  Yanagisawa, Breann L ^a   Resar, Linda M S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer stem cells; embryonic stem cells; epithelial mesenchymal transition; high mobility group A1 protein; HMGA1

Indexed keywords

HERMES ANTIGEN; HIGH MOBILITY GROUP A1A PROTEIN; HIGH MOBILITY GROUP A1B PROTEIN; HISTONE H1; PROTEIN SWI; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SNF;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLORECTAL CANCER; DRUG TARGETING; EMBRYONIC STEM CELL; ERADICATION THERAPY; GENE; GENE SILENCING; GROWTH RATE; HEMATOLOGIC MALIGNANCY; HISTONE ACETYLATION; HMGA1A GENE; HMGA1B GENE; HUMAN; METASTASIS INHIBITION; METASTASIS POTENTIAL; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR ESCAPE; TUMOR INVASION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; EMBRYONIC STEM CELLS; HMGA1A PROTEIN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84893059106     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2013.859988     Document Type: Article

References (82)

1. Dick JE. Stem cell concepts renew cancer research. Blood 112, 4793-4807 (2008
2. McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol. Oncol. 4, 404-419 (2010
3. Marjanovic ND, Weinberg RA, Chaffer CL. Cell Plasticity and Heterogeneity in Cancer. Clin. Chem. 59(1), 168-179 (2013
4. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296 (2012
5. Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A. Pancreatic carcinogenesis. Pancreatol. 8(2), 110-125 (2008
6. Hristov A, Cope L, Di Cello F et al. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod. Pathol. 23, 98-104 (2010
7. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012
8. Gerber JM, Smith DB, Ngwang B. Clinically relevant population of leukemic CD34 +CD38-cells in acute myeloid leukemia. Blood 119(12) 3571- 3577 (2012
9. Ben-Porath MW, Thomson VJ, Carey R. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499-507 (2008
10. Shah SN, Kerr C, Cope L et al. HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS ONE 7(11), e48533 (2012
11. Belton A, Gabrovsky A, Kyung Bae Y et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS ONE 7(1), e30034 (2012
12. Shah SN, Cope L, Poh W et al. HMGA1: A master regulator of tumor progression in triple negative breast cancer. PLoS ONE 8(5), e63419 (2013
13. Reeves R, Beckerbauer L. HMGI/Y proteins: Flexible regulators of transcription and chromatin structure. Biochim. Biophys. Acta 1519, 13-29 (2001
14. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 7, 899-910 (2007
15. Resar LMS. High mobility group A1 gene: Transforming inflammation into cancer? Cancer Res. 70(2), 436-439 (2010
16. Johnson KR, Lehn DA, Elton TS, Barr PJ, Reeves R. Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y). J. Biol. Chem. 263, 18338-18342 (1988
17. Friedmann M, Holth LT, Zoghbi HY, Reeves R. Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nuc. Acids Res. 21, 4259-4267 (1993
18. Pedulla ML, Treff NR, Resar LMS, Reeves R. Sequence and analysis of the murine Hmgiy (Hmga1) gene locus. Gene 271, 51-58 (2001
19. Lund T, Holtlund J, Fredriksen M, Laland SG. On the presence of two new high mobility group-like proteins in HeLa S3 cells. FEBS Lett. 152, 163-167 (1983
20. Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol. Cell Biol. 21, 575-594 (2001
21. Martinez Hoyos J, Fedele M, Battista S et al. Identification of the genes up- And down-regulated by the high mobility group A1 (HMGA1) proteins: Tissue specificity of the HMGA1-dependent gene regulation. Cancer Res. 64, 5728-5735 (2004
22. Schuldenfrei A, Belton A, Kowalski J et al. HMGA1 drives inflammatory pathways, cell cycle progression, and embryonic stem cell genes during lymphoid tumorigenesis. BMC Genomics 12, 549 (2011
23. Thanos D, Maniatis, T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 71, 777-789 (1992
24. Du W, Maniatis T. The high mobility group protein HMG I(Y) can stimulate or inhibit DNA binding of distinct transcription factor ATF-2 isoforms. Proc. Natl Acad. Sci. USA 91, 11318-11322 (1994
25. Falvo JV, Thanos D, Maniatis T. Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell 83, 1101-1111 (1995
26. Thanos D, Maniatis T. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 83, 1091-1100 (1995
27. Munshi N, Agalioti T, Lomvardas S, Merika M, Chen G, Thanos D. Coordination of a transcriptional switch by HMGI(Y) acetylation. Science 293, 1133-1136. (2001
28. Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-beta enhanceosome. Cell 129, 1111-1123 (2007
29. E Ford, D. Thanos. The transcriptional code of human IFN-b gene expression. Biochem. Biophy. Acta 1799, 328-336 (2010
30. Saitoh Y, Laemmli UK. Metaphase chromosome structure: Bands arise from a differential folding path of the highly AT-rich scaffold. Cell 76, 609-622 (1994
31. Girard F, Bello B, Laemmli UK, Gehring WJ. (1998) In vivo analysis of scaffold-Associated regions in Drosophila: A synthetic high-Affinity SAR binding protein suppresses position effect variegation. EMBO J. 7, 2079-2085 (1998
32. Zhao K, Kas E, Gonzalez E., Laemmli UK. SAR-dependent mobilization of histone H1 by HMG-I/Y in vitro: HMG-I/Y is enriched in H1-depleted chromatin. EMBO J. 12, 3237-3247 (1993
33. Strick R, Laemmli UK. SARs are cis DNA elements of chromosome dynamics: Synthesis of a SAR repressor protein. Cell 83, 1137-1148 (1995
34. Mirkovitch J, Mirault ME, Laemmli UK. Organization of the higher-order chromatin loop: Specific DNA attachment sites on nuclear scaffold. Cell 39, 223-232 (1984
35. Reeves R, Wolffe AP. Substrate structure influences binding of the non-histone protein HMG-I(Y) to free nucleosomal DNA. Biochemistry 35, 5063-5074 (1996
36. Reeves R, Leonard WJ, Nissen MS. 2000. Binding of HMG-I(Y) imparts architectural specificity to a positioned nucleosome on the promoter of the human interleukin-2 receptor alpha gene. Mol. Cell Biol. 20, 4666-4679 (2000
37. Himes SR, Reeves R, Attema J, Nissen M, Li Y, Shannon MF. The role of high-mobility group I(Y) proteins in expression of IL-2 and T-cell proliferation. J. Immunol. 164, 3157-3168 (2000
38. Attema JL, Reeves R, Murray V, Levichkin I, Temple MD, Tremethick DJ, Shannon MF. The human IL-2 gene promoter can assemble a positioned nucleosome that becomes remodeled upon T-cell activation. J. Immunol. 169, 2466-2476(2002
39. Henderson A, Holloway A, Reevers R, Tremethick DJ. Recruitment of SWI/SNF to the human immunodeficiency virus type 1 promoter. Mol. Cell Biol. 24, 389-397 (2004). Special Report Yanagisawa & Resar 28 Expert Rev. Anticancer Ther. 14(1), (2014
40. Chiappetta G, Avantaggiato V, Visconti R et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13, 2439-2446 (1996
41. Zhou G, Chen J, Lee S, Clark T, Rowley JD, Wang SM. The pattern of gene expression in human CD34+ stem/ progenitor cells. Proc. Natl Acad. Sci. USA 98, 13966-13971 (2001
42. Chou B-K, Mali P, Huang X et al. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with a unique epigenetic and gene expression signatures. Cell Res. 11, 518-529 (2011
43. Karp JE, Smith BD, Resar LMS et al. Phase I and pharmacokinetic study of "hybrid" (bolus-infusion) flavopiridol administered followed in time sequence by cytosine arabinoside and mitoxantrone for adults with relapsed and refractory acute leukemias. Blood 117, 3302-3310 (2011
44. Nelson DM, Joseph B, Hillion J, Segal J, Karp J, Resar LMS. Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk. Lymphoma 52, 1999-2006 (2011
45. Munoz J, Stange DE, Schepers AG et al. The Lgr5 intestinal stem cell signature: Robust expression of proposed quiescent +4 markers. EMBO J. 31, 3079-3091 (2012
46. Battista S, Pentimalli F, Baldassarre G. Loss of HMGA1 gene function affects embryonic stem cell lympho-hematopoietic differentiation. FASEB J. 17, 1496-1498 (2003
47. Foti D, Chiefari E, Fedele M et al. Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat. Med. 11, 765-773 (2005
48. Fedele M, Fidanza V, Battista S et al. Haploinsufficiency of the HMGA1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res. 66, 2536-2543 (2006
49. Xu Y, Sumter Felder T, Bhattacharya R. The HMG-I oncogene causes highly penetrant, metastatic lymphoid malignancy in transgenic mice and is overexpressed in human lymphoid malignancy. Cancer Res. 64, 3371-3375 (2004
50. Fedele M, Pentimalli F, Baldassarre G et al. Transgenic mice overexpressing the wild-Type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 24, 3427-3435 (2005
51. Tesfaye A, Di Cello F, Hillion J et al. The High-Mobility Group A1 gene up-regulates Cyclooxygenase-2 expression in uterine tumorigenesis. Cancer Res. 67, 3998-4004 (2007
52. Di Cello F, Dhara S, Hristov A et al. Inactivation of the Cdkn2a locus cooperates with HMGA1 to drive T-cell leukemogenesis. Leuk. Lymphoma 54(8), 1762-1768 (2013
53. Somervaille TC, Matheny CJ, Spencer GJ et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4, 129-140 (2009
54. Wood LJ, Mukherjee M, Dolde CE et al. HMG-I/Y: A new c-Myc target gene and potential human oncogene. Mol. Cell Biol. 20, 5490-5502 (2000
55. Wood LJ, Maher J, Bunton TE, Resar LMS. The oncogenic properties of the HMG-I gene family. Cancer Res. 60, 4256-4261 (2000
56. Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonaltumour outcome based on gene expression. Nature 415, 436-442 (2002
57. Takaha N, Resar LMS, Vindivich D, Coffey D. High mobility protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate 60, 160-167 (2004
58. Hommura F, Katabami M, Leaner VD et al. HMG-I/Y is a cJun/AP-1 responsive gene and is necessary for cJun induced anchorage-independent growth. Mol. Cancer Res. 2, 303-314 (2004
59. Shah S, Resar LMS. HMGA1 in Cancer: Potential biomarker and therapeutic target. Histol. Histopath. 27, 567-579 (2012
60. Roy S, Di Cello F, Kowalski J . HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. Leuk. Lymphoma 54(11), 2565-2567 (2013
61. Dolde CE, Mukherjee M, Cho C, Resar LMS. The role of HMG-I/Y in human breast cancer cells. Breast Cancer Res. Treat. 71, 181-191 (2002
62. Hillion J, Wood LJ, Mukerjee M et al. Up-regulation of matrix metalloproteinase-2 by HMGA1 promotes transformation in undifferentiated, large cell human lung cancer. Mol Cancer Res. 7, 1803-1812 (2009
63. Hillion J, Dhara S, Sumter TF et al. The HMGA1a-STAT3 axis: An "Achilles heel" for hematopoietic malignancies? Cancer Res. 68, 10121-10127 (2008
64. Liau SS, Jazag A, Whang EE. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res. 66, 11613-11622 (2006
65. Sarhadi VK, Wikman H, Salmenkivi K et al. Increased expression of high mobility group A proteins in lung cancer. J. Pathol. 209, 206-212 (2006
66. Mani SA, Guo W, Liao M J et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008
67. Lim J, Thiery JP. Epithelial-mesenchymal transitions: Insights from development. Development 139(19), 3471-3486 (2012
68. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Sem. Cancer Biol. 22, 396-401 (2012
69. Dhar A, Hu J, Reeves R, Resar L, Colburn N. Dominant negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene 23, 4466-4476 (2004
70. Scala S, Portella G, Fedele M, Chiappetta G, Fusco A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc. Natl Acad. Sci. USA 97, 4256-4261 (2000
71. Foster LC, Wiesel P, Huggins GS et al. Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1beta in vascular smooth muscle cells. FASEB J. 14, 368-378 (2000
72. Beckerbauer L, Tepe JJ, Cullison J. FR900482 class of anti-Tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo. Chem. Biol. 7, 805-812 (2000
73. Beckerbauer L, Tepe JJ, Eastman RA Differential effects of FR900482 and FK317 on apoptosis, IL-2 gene expression, and induction of vascular leak syndrome. Chem. Biol. 9, 427-441 (2002
74. Ma W, Oriz-Quintero B, Rangel R, et al. Innate activation of inflammatory gene networks, alveolar destruction and neonatal death in AKNA deficient mice. Cell Res. 21, 1564-1577 (2011
75. Moliterno A, Resar L. AKNA : Another AT-hook transcription factor hooking up with inflammation. Cell Res. 21, 1528-1530 (2011
76. Di Cello F, Hillion J, Aderinto A et al. COX-2 inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human uterine cancer xenografts. Mol. Cancer Ther. 7(7), 2090-2095 (2008
77. Hillion J, Di Cello F, Belton A. Nanoparticle delivery of inhibitory STAT3 GQ-oligonucleotides blocks tumor growth in an HMGA1 transgenic model of T-cell leukemia. Leuk. Lymphoma doi:10.3109/ 10428194.2013.821202 (2013) (Epub ahead of print
78. Boylan NJ, Suk JS, Lai SK et al. Highly compacted DNA nanoparticles with low MW PEG coatings: In vitro, ex vivo and in vivo evaluation. J. Control. Release 157, 72-79 (2012
79. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63, 185-198 (2012
80. Pramanik D, Campbell NR, Karikari C et al. Resititution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol. Cancer Ther. 10, 1470-1480 (2011
81. Mussnich P, D'Angelo D, Leone V, Croce CM, Fusco A. The high mobility group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression. Mol. Oncol. 7, 531-542 (2013
82. Resar LMS, Brodsky RA. "Let"-ing go with clonal expansion? Blood 117, 5788-5790 (2011